ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

YMBA YM Bio. Com Shs

75.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
YM Bio. Com Shs LSE:YMBA London Ordinary Share CA9842381050 COM SHS NPV
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 75.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
  -
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 75.00 GBX

YM Bio. Com Shs (YMBA) Latest News

Real-Time news about YM Bio. Com Shs (London Stock Exchange): 0 recent articles

YM Bio. Com Shs (YMBA) Discussions and Chat

YM Bio. Com Shs Forums and Chat

Date Time Title Posts
13/12/201202:05Canadian Cuban Cancer Curio135

Add a New Thread

YM Bio. Com Shs (YMBA) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

YM Bio. Com Shs (YMBA) Top Chat Posts

Top Posts
Posted at 13/12/2012 02:05 by rambutan2
An early Christmas present, albeit a long awaited one...

FOSTER CITY, CA AND MISSISSAUGA, ON, Dec. 12, 2012 /CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) and YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) announced today that the companies have signed a definitive agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. The transaction has received the unanimous approval of YM's Board of Directors, and values YM at approximately U.S.$510 million, with YM reporting C$125.5 million in cash and cash equivalents as of September 30, 2012. Gilead plans to fund the acquisition with cash on hand. The transaction is expected to close in the first quarter of 2013.



Terms of the Transaction
Under the terms of the agreement, upon closing of the proposed transaction, shareholders of YM will receive U.S.$2.95 per common share in cash, and holders of warrants and stock options will receive a cash payment equal to the difference between U.S.$2.95 and the exercise price of such warrant or stock option. The proposed transaction will be completed through a plan of arrangement under the provisions of the Companies Act (Nova Scotia).

The transaction will require the approval of YM shareholders at a special meeting of YM shareholders, to be held as soon as reasonably practicable and in any event on or before February 11, 2013. In addition to YM's shareholder approval, closing of the transaction is subject to the satisfaction of certain other customary conditions, including court approval of the transaction, and applicable government and regulatory approvals, including expiration or termination of the waiting period under the United States Hart Scott Rodino Antitrust Improvements Act, and the review period under the Competition Act (Canada). The approval of Gilead shareholders is not required in connection with the proposed transaction.

The arrangement agreement contains customary non-solicitation provisions, but permits YM, in certain circumstances, to terminate the arrangement and accept an unsolicited superior proposal, subject to fulfilling certain conditions.

BofA Merrill Lynch and Bloom Burton & Co. serve as financial advisors, and Gowling Lafleur Henderson LLP, Heenan Blaikie LLP and Dorsey & Whitney LLP serve as legal advisors to YM in connection with the transaction. Gilead is advised by Wilson Sonsini Goodrich & Rosati, Professional Corporation and Blake Cassels and Graydon LLP.
Posted at 24/12/2010 17:48 by rambutan2
has been going well and gathering increasing interest since last post...



MISSISSAUGA, ON, Dec. 23 /PRNewswire/ - YM BioSciences Inc. (YMI) announced today that, in connection with its previously announced public offering for total net proceeds before expenses of US $37,650,000, the underwriters have exercised in full their Over-Allotment Option to purchase an additional 3,750,000 common shares of YM at US $1.60 per share for additional net proceeds of US $5,665,000.
Posted at 27/8/2009 16:22 by dutch alert
Hi Analcime

On Canada symbol YM
On US symbol YMI
Also on Germany but I have no symbol of that
Also quoted in London symbol YMBA
Liquidity is best in US

On the run again today. I am happy.
Posted at 25/8/2009 16:04 by dutch alert
YMI on fire - Griffin sec. gives a 12 months target of 5$US

# ERBITUX® AND VECTIBIX® LIKELY TO BE SUPPLANTED BY YMI'S NIMOTUZUMAB AS THE EGFR MONOCLONAL ANTIBODY OF CHOICE IN A GREAT MAJORITY OF TUMORS. There has been a profound change in the scientific understanding of nimotuzumab, as described in a poster presented at the recent AACR annual meeting entitled, "Binding properties of the anti-EGFR monoclonal antibody nimotuzumab limit its interaction with the EGFR in renal and epidermal cells."1 Nimotuzumab is an affinity-optimized antibody that, by virtue of its lower affinity than the marketed EGFR mAbs, depends on avidity (bivalent binding) for definitive attachment to the receptors, avoids normal tissue, and is clinically effective in those circumstances where there is a moderate-to-high expression of EGF receptor. As demonstrated by YMI, this occurs naturally in high-expressing tumor cells, such as in head and neck, glioma, cervical, and gastric cancers, and also in indications where any radiation-containing treatment is utilized (e.g., NSCLC). The low-expressing tumor cell type tumors other than those treated with radiation-containing regimens are not targets for nimotuzumab. While refractory colorectal cancer would be a low-expressing cancer not amenable to treatment with nimotuzumab, the rectal cancer component (approximately 20%) would fit the radiation-treated category. We believe the implications of these findings and the related value to both cancer patients and shareholders are potentially substantial given that nimotuzumab will prospectively be an important competitor to Erbitux®, whose 2008 sales were $1.5 billion, and for which Eli Lilly (NYSE: LLY) recently acquired ImClone Systems for $6 billion.
# ? STRONG GLOBAL PARTNERS SUPPORT NIMOTUZUMAB CLINICAL DEVELOPMENT. Nimotuzumab has completed 20 clinical trials around the world, and, notably, nimotuzumab is already approved for sale in India, China, Indonesia, the Philippines and 16 other developing countries, Importantly, the drug is in later stage clinical trials in major global markets with YMI's licensees, which include Daiichi-Sankyo in Japan, Oncoscience AG in Western Europe, Kuhnil Pharma Co. in Korea, and Innogene Kalbiotech/Kalbe Farma in Singapore. Each licensee is funding clinical trials in their respective regional markets, and YMI is entitled to a royalty on revenue upon commercialization. There are another 32 clinical trials ongoing worldwide in various solid tumors.2
# ? U.S. GOVERNMENT CLEARS THE WAY FOR NIMOTUZUMAB SOLID TUMOR TRIALS. On August 10, 2009, YMI announced that the Company's wholly-owned subsidiary YM BioSciences USA, Inc. received permission from the U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) to develop nimotuzumab, in solid tumors in the U.S.3 This permission allows YMI to undertake multiple clinical trials in the U.S. and provides positive momentum towards realizing its eventual commercial goals in the U.S. The Company has already commenced discussions with the FDA for permission to include U.S. patients in its current palliative lung cancer and brain metastases from lung cancer trials. The Company has also applied for a license to market nimotuzumab if approved by the FDA, which would be necessary to commercialize the product in the U.S. Plans to commence commercialization discussions with pharmaceutical companies are underway.
# ? EFFICACY DATA FROM NIMOTUZUMAB'S PHASE IIB TRIAL IN HEAD & NECK CANCER PRESENTED AT ASCO. The Phase IIb ("BEST") randomized clinical trial demonstrated that the efficacy of nimotuzumab compares favorably to results reported for Erbitux® and showed a statistically significant difference in overall survival (p=0.0018) between the arms. Significantly, this randomized trial supports the mechanism data that demonstrates that patients showed essentially

1. equivalent clinical benefit from nimotuzumab in high-EGFR expressing cells (SCCHN >80%) without the numerous severe toxicities of Erbitux®.4
2. ? YMI SHARES REPRESENT EXCEPTIONAL VALUE. Given that the Company is trading near its cash balances of approximately $37 million as of March 31, 2009, nimotuzumab's recent green light by the U.S. government for its development in the U.S., and the prospect of being best-in-class in an established and currently marketed class of billion dollar drugs, we believe the upside for the nimotuzumab asset and YMI is exceptional. Our valuation model supports a 12-month target price of $5.00 per share; therefore, we reiterate our BUY recommendation on YM BioSciences, Inc. and establish a new 12-month target price of $5.00 per share.
Posted at 01/9/2007 23:15 by rambutan2
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of
nimotuzumab in children with inoperable, recurrent brain cancer MISSISSAUGA, ON, Aug. 30 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that its wholly-owned US subsidiary, YM BioSciences USA Inc. ("YM-USA") has been cleared by the US Food and Drug Administration (FDA) to initiate a Phase II trial investigating nimotuzumab in pediatric patients with recurrent diffuse
intrinsic pontine glioma (DIPG), a form of inoperable, treatment-resistant
brain cancer. Nimotuzumab is a humanized monoclonal antibody that targets the
epidermal growth factor receptor (EGFR). Eight leading US pediatric clinical
centers will be participating in the study. YM BioSciences previously
announced that it had received a No Objection Letter from Health Canada in
June 2007 to initiate this single-arm trial, which will enrol 44 patients with
DIPG who will be treated with nimotuzumab as monotherapy. This is the first occasion, to the knowledge of the Company, in which a clinical trial has been cleared by the FDA for a drug of Cuban origin.Clearance for importation of nimotuzumab into the US for this trial was authorized by a Special License issued to YM-USA by the US Treasury Department's Office of Foreign Assets Control (OFAC). Nimotuzumab has already been administered to a number of children in the US under licenses from the US Treasury Department and under single-patient INDs from the FDA. "The clearance of this US IND by the FDA is a significant step in the development of nimotuzumab," said David Allan, Chairman and CEO of YM BioSciences. "In addition to the US investigatory sites, the global development program for nimotuzumab includes ongoing and planned clinical
trials involving this and various other indications of cancer in Canada,
Europe, Japan, Korea, Singapore, India, Argentina, and Brazil."
The trial design is based on a previous trial conducted in Germany. In
that trial, which was the subject for an oral presentation at ASCO 2007, eight
of 21 children with recurrent DIPG had a clinical benefit from treatment with
nimotuzumab as monotherapy - one Partial Response (PR) and seven Stable
Disease (SD) were reported in 21 patients, at the end of the induction phase
at the eighth week. Those eight patients continued on maintenance therapy and,
at week 21, three patients were declared PR and one was evaluated SD. No
reports of OR in this patient population has, to the knowledge of the Company,
been previously reported. The primary endpoint of the current trial is Response Rate, with a target of 15%, and recruitment is expected to be completed within approximately 18 months from initiation. The principal investigatory site is the Hospital for Sick Children in Toronto, Canada where Drs. Eric Bouffet, Sylvain Baruchel, and Ute Bartels lead the international program. The US investigatory
sites at which the trial will be conducted include leading pediatric neuro-oncology centers that are members of the "POETIC" consortium (Pediatric Oncology Experimental Therapeutics International Consortium). Members of POETIC include Vanderbilt Children's Hospital/Vanderbilt-Ingram Cancer Center, M.D. Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, the Sidney Kimmel Cancer Center at Johns Hopkins, Children's Healthcare of Atlanta at Egleston, the Children's Hospital at the University of Colorado and the University of Florida and Alberta's Children's Hospital in Calgary. In addition, the University of Rochester Medical Center and the New York University Medical Center will also be included in the trial. YM BioSciences' European partner for the development of nimotuzumab, Oncoscience AG, recently announced the enrolment of the 40th and final patient in its international Phase III trial combining nimotuzumab with radiation for the first-line treatment of children and adolescents with newly diagnosed DIPG.
Posted at 09/7/2007 22:53 by rambutan2
YM BioSciences announces preclinical data confirming nimotuzumab binds to the
EGF receptor and potentiates radiotherapy

MISSISSAUGA, ON, July 9 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM,
AIM: YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today announced that a study
presented by investigators from Kinki University School of Medicine and Kyoto
University at the 11th meeting of The Japanese Association for Molecular
Target Therapy of Cancer held on July 5-6, 2007 demonstrated the increased
radiosensitivity of human NSCLC cell lines in the presence of nimotuzumab both
in vitro and in vivo. The study also confirms previous observations that
nimotuzumab inhibits ligand-dependent EGF receptor downstream signaling.
Daiichi Sankyo Co., Ltd is the licensee for nimotuzumab in Japan.

In addition, YM BioSciences announced that a paper on the structure of
nimotuzumab entitled 'Modeling the interaction between the anti-tumor antibody
h-R3 and its target, the epidermal growth factor receptor' was presented at
the 11th annual meeting of the SBNet (Structural Biology Network), held on
June 15-18, 2007 in Tallberg, Sweden. The paper demonstrated that nimotuzumab
specifically competes with cetuximab for binding to the EGF receptor. The
authors noted that, "According to our models, nimotuzumab inhibits the EGFr
signaling both by inhibiting the binding of EGF to domain III of EGFr and by a
conformational change of EGFr that is necessary to shape the EGF binding
site."

"These two studies provide independent confirmation of earlier research
indicating that nimotuzumab directly binds to the EGF receptor," said Dr. Igor
Sherman, Director of Clinical Research at YM BioSciences. "The very rare
incidence, in patients treated with nimotuzumab, of the commonly seen
side-effects of EGFr-targeting therapy, such as rash and diarrhea, has raised
questions about whether nimotuzumab is truly interacting with the EGF
receptor. The data presented at SBNet provides further evidence that
nimotuzumab binds to the receptor, while the independent data from Kinki and
Kyoto demonstrated the synergistic effect of nimotuzumab and radiation on
cancer cells and inhibition of EGFr down-stream signaling in the presence of
nimotuzumab."

"We conclude that nimotuzumab behaves no differently than the other
EGFr-targeting antibodies and that the limited and rare incidences of the
debilitating side-effects that are commonly seen with other antibodies and
small molecules targeting the tyrosine kinase pathway indicates that
nimotuzumab has the prospect of being "best-in-class" without compromised
efficacy," said David Allan, Chairman and CEO of YM BioSciences.
Posted at 21/7/2006 11:49 by rambutan2
all still ticking along (ignoring share price fluctuations) nicely over last couple of months...
Posted at 05/4/2006 02:19 by rambutan2
up on other side of pond yesterday due to...

YMI YM BioSciences initiated with a Buy and a $15 price target at AG Edwards (5.69 )

Key points:

1. $15 valuation based strictly on 2010 revenue estimate of approximately $160 million in sales for tesmilifene on $465 million on sales with a price of about $9600 per patient per year.

2. They note that TELK has a market cap of $1 billion although "Telik does not have positive data from a phase III trial (where YM does) nor does it have a robust pipeline."

3. They add only $100 million for the value of the non-tesmilifene pipeline (only nimo and AeroLef); nevertheless they think YMI will have a 2007 value of roughly $800 million

4. They did not include the propargylamines or Norelin in their valuation calculation.
Posted at 09/3/2006 01:48 by rambutan2
few snippet of conversation from 03/03/06 stateside, where tradeable options on ym have just been made available...

Over $1 million was bet today that YMI will be over $9 by October. The average call sold for $1.50, expiring in Oct for a $7.50 strike. The sell side was willing to take the $1.50 plus the possible $7.50 to receive $9 for stock they probably paid $4.25 for. Nice gain. The buy side thinks the stock will be sufficiently higher than $9 to risk $1 million aggregate by October.

Wow. (I was a writer of some of the puts today, the $5 strike July and October. If the results are delayed or poor, I'll have the stock put to me at around $3.30 to $3.50 net. That's an OK bet I think.)

Let me clarify that last post. I don't think it's amazing that the price would be over $9 at the tesmilifene announcement. I think it's amazing that such large bets were placed on the options expiring in July at the higher strike price. That is confidence that the news will be released when YMI said it would and that the news will be good and that the market will respond at a price sufficiently higher than $9 to make it a worthwhile bet to risk well over $1 million.

I prefer to just own the stock.

however...
the biggest bet today was the sell (at bid and below, $0.85 - 1.05 at 1.24PM) of 5000 contracts (ie 500k (!) shares) of 7.5 Jul calls; someone bets huge money this stock will be below 7.5 by July, or it's someone with big stock position, 50k shares or more, covering (personally, i don't believe that)

but...
Even if the stock is over $7.50, that seller will receive around $8.50 per share with the option premium. If they were one of the $4.25 secondary offering investors, that's a pretty good rate of return for a few months. Maybe they don't expect results by the July expiration date.
Posted at 14/2/2006 14:47 by rambutan2
no complaints at $4.25 ie £2.45...

YM BioSciences raises US $ 40 million
Tuesday February 14, 9:31 am ET

MISSISSAUGA, Canada, Feb. 14 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), the cancer product development company, today announced that it has received subscriptions for approximately 9.5 million common shares in a "registered direct" offering at an issue price of US $4.25 for gross proceeds of approximately US $40 million. SG Cowen & Co., LLC served as lead placement agent and Dundee Securities Corporation and Canaccord Capital Corporation served as co-placement agents for the transaction.

The funds will be used principally to fund YM's drug development activities and for general corporate purposes.

Subscribers for the issue included leading health care institutional investors led by Great Point Partners, LLC

The transaction is expected to close on or about February 17, 2006, pending stock exchange approval.
YM Bio. Com Shs share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock